Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06925542 · ClinicalTrials.gov registry record · Phase 1
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
A Phase 1 study of Lupus Nephritis and Lupus Erythematosus, Systemic, sponsored by CRISPR Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 8
- Study locations
NCT06925542 is a Phase 1 study of Lupus Nephritis and Lupus Erythematosus, Systemic that is actively recruiting participants, run by CRISPR Therapeutics. The registered enrollment target is 80 participants, below the 308-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (74% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT06925542, a Phase 1 study of Lupus Nephritis and Lupus Erythematosus, Systemic, is actively recruiting participants, sponsored by CRISPR Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM).
Conditions Studied
Interventions
- BIOLOGICAL CTX112
Study Locations (8)
Other
- Research Site 7 - Augsburg
- Research Site 3 - Hanover
California
- Research Site 4 - Redwood City
Illinois
- Research Site 2 - Chicago
Iowa
- Research Site 8 - Iowa City
Massachusetts
- Research Site 6 - Boston
Missouri
- Research Site 1 - St Louis
North Carolina
- Research Site 5 - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-03-10 |
| Est. Completion | 2031-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06925542
The ClinicalTrials.gov registry entry for NCT06925542 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 308-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (74% lower). The listed sponsor is CRISPR Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Lupus Nephritis appearing as the primary indexed condition, and to 1 intervention - of which CTX112 is the first listed.
NCT06925542 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT06925542 about?
NCT06925542 is a clinical study titled "A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease". This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopat...
What is the current status of trial NCT06925542?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2025-03-10. Estimated completion is 2031-12-31.
What conditions does trial NCT06925542 study?
This clinical trial studies the following conditions: Lupus Nephritis, Lupus Erythematosus, Systemic, Systemic Sclerosis, Myositis, SLE (Systemic Lupus).
What interventions are being tested in trial NCT06925542?
The interventions under investigation include: CTX112 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06925542?
This trial is sponsored by CRISPR Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06925542 being conducted?
This trial has 8 study locations across California, Illinois, Iowa, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Nephritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RECRUITING · Phase 1
-
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
RECRUITING · Phase 1
-
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old
ACTIVE NOT RECRUITING · Phase 1
-
KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
ACTIVE NOT RECRUITING · Phase 1
-
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.